New book by Larry Connors Click here Improve your trading - See how
Taylor Technology and Anapharm representatives will be discussing their offerings in method development and validation, bioanalytical mass spectrometry and immunochemistry. For more information on PharmaNet Development Group and the offering of its subsidiaries, please visit the PharmaNet booth 1739 at AAPS 2009 at the Los Angeles Convention Center, Los Angeles, California from November 8 - 11, 2009.
Attendees of the conference are invited to attend a series of poster presentations by PharmaNet employees covering a wide range of scientific topics and will include the following topics:
Tuesday, November 10, 2009
Presentations from 11:00 am to 12:00 pm, Posters available from 8:00 am to 12:00 pm
Importance of Using Physiologically-Relevant Concentrations in the Evaluation of Metabolite Back-Conversion, Presenter: Betty Stamatiou, Co-Authors: Sylvain Lachance, Ann Levesque, Robert Masse, Betty Stamatiou
A Useful Derivatization Tool to Enhance Sensitivity for the Quantitation of Phenylephrine at Low Picograms levels by LCMSMS, Presenter: Ann Levesque, Co-Authors: Serge Auger, Sylvain Lachance, Ann Levesque, Robert Masse
Relative Instability of Deuterated Internal Standard under Different pH Conditions and According to Deuterium Atoms Location, Presenter: Nathalie Pelletier, Co-Authors: Nadine Boudreau, Sylvain Lachance, Ann Levesque, Robert Masse, Nathalie Pelletier, Caroline Savard
Precautions Required to Quantify a Thermally Labile [beta]-lactone in Human Plasma by LC/MS/MS, Presenter: Stephanie Turcotte, Co-Authors: Sylvain Lachance, Ann Levesque, Robert Masse, Stephanie Turcotte
Summation of Multiple Transitions Monitoring in LC/MS/MS to Enhance Signal to Noise and to Reduce Variability, Presenter: Sylvain Lachance, Co-Authors: Philippe Belanger, Jean Couture, Sebastien Gagne, Sylvain Lachance, Ann Levesque, Isabelle Levesque, Robert Masse, François Viel
A Useful Computerized Tool for the Evaluation of Bioanalytical Methods and Study Sample Analysis Robustness, Presenter: Nadine Boudreau, Co-Authors: Patrice Arcand, Serge Auger, Philippe Belanger, Nadine Boudreau, Ann Levesque, Robert Masse
How to Avoid Metabolite Back-Conversion: Tests Performed to Prove the Absence of Back-Conversion for Clopidogrel LCMSMS Method in Human Plasma, Presenter: Guy Havard, Co-Authors: Marie-Eve Coulombe, Guy Havard, Sylvain Lachance, Ann Levesque, Robert Masse
Lipemic Effect Evaluation on Detection Variability Using Natural and Synthetic Lipemic Plasma in LC/MS/MS Method, Presenter: Sofi Gagnon-Carignan, Co-Authors: Sofi Gagnon-Carignan, Sylvain Lachance, Nancy Lampron, Ann Levesque, Robert Masse
Trouble-Shooting of Least-Expected Causes in Bioanalytical Method Development and Application, Presenter: Aimin Tan, Co-Authors: Sebastien Gagne, Robert Masse, Valerie Montminy, Adrien Musuku, Aimin Tan
Wednesday, November 11, 2009
Presentations from 11:00 am to 12:00 pm, Posters available from 8:00 am to 12:00 pm
Quantification of the Impact of Bioanalytical Method Variability on Bioequivalence Primary Pharmacokinetic Parameters, Presenter: Audrey Saint-Laurent, Co-Authors: Audrey Lainesse, Robert Masse, Audrey Saint-Laurent, Eric Shink, Mario Tanguay
Thursday, November 12, 2009
Presentations from 11:00 am to 12:00 pm, Posters available from 8:00 am to 12:00 pm
Enantiomeric Separation in Chiral Chromatography Enhanced by Propionic Anhydride as a Chemical Modifier, Presenter: Robert Masse, Co-Authors: Nicolas Jean, Sylvain Lachance, Ann Levesque, Robert Masse
For more information about PharmaNet and its subsidiaries' comprehensive range of services, please visit the PharmaNet Development Group booth 1739 at AAPS 2009. Alternatively, please email earlystage@pharmanet.com or visit www.pharmanet.com
About PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development.
For further press information please contact Celine Callender, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email: pharmanet@scottpr.com
Media Contact Information
Name: Celine Callender/Laura Browne Anne-Marie Hess
Scott Partnership PharmaNet Development Group, Inc.
Phone: +44 1477 539539 (609) 951-6842
Email: pharmanet@scottpr.com ahess@pharmanet.com
SOURCE PharmaNet Development Group, Inc.
http://www.pharmanet.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.